Cargando…

The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study

The purpose of this study was to investigate the cardioprotective effect of the semisynthetic flavonoid 7-monohydroxyethylrutoside (monoHER) on doxorubicin (DOX)-induced cardiotoxicity in a phase II study in patients with metastatic cancer. Eight patients with metastatic cancer were treated with DOX...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruynzeel, A M E, Niessen, H W M, Bronzwaer, J G F, van der Hoeven, J J M, Berkhof, J, Bast, A, van der Vijgh, W J F, van Groeningen, C J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360436/
https://www.ncbi.nlm.nih.gov/pubmed/17940501
http://dx.doi.org/10.1038/sj.bjc.6603994
_version_ 1782153049018466304
author Bruynzeel, A M E
Niessen, H W M
Bronzwaer, J G F
van der Hoeven, J J M
Berkhof, J
Bast, A
van der Vijgh, W J F
van Groeningen, C J
author_facet Bruynzeel, A M E
Niessen, H W M
Bronzwaer, J G F
van der Hoeven, J J M
Berkhof, J
Bast, A
van der Vijgh, W J F
van Groeningen, C J
author_sort Bruynzeel, A M E
collection PubMed
description The purpose of this study was to investigate the cardioprotective effect of the semisynthetic flavonoid 7-monohydroxyethylrutoside (monoHER) on doxorubicin (DOX)-induced cardiotoxicity in a phase II study in patients with metastatic cancer. Eight patients with metastatic cancer were treated with DOX preceded by a 10 min i.v. infusion of 1500 mg m(−2) monoHER. Five patients were examined by endomyocardial biopsy after reaching a cumulative dose of 300 mg m(−2). Histopathological changes in the cardiomyocytes (Billingham score) were compared with those described in literature for patients treated with DOX only. The mean biopsy score of the patients was higher (2.7) than the mean score (1.4) of historical data of patients who received similar cumulative doses of DOX. Although there is a considerable variability in few investigated patients, it was indicative that monoHER enhanced DOX-induced cardiotoxicity. However, the antitumour activity of DOX seemed better than expected: three of the four patients with metastatic soft-tissue sarcoma had a partial remission and the fourth patient stable disease. It is likely that the relatively high dose of monoHER is responsible for the lack of cardioprotection and for the high response rate in patients with soft-tissue sarcoma possibly by depleting the glutathione defense system in both heart and tumour.
format Text
id pubmed-2360436
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23604362009-09-10 The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study Bruynzeel, A M E Niessen, H W M Bronzwaer, J G F van der Hoeven, J J M Berkhof, J Bast, A van der Vijgh, W J F van Groeningen, C J Br J Cancer Translational Therapeutics The purpose of this study was to investigate the cardioprotective effect of the semisynthetic flavonoid 7-monohydroxyethylrutoside (monoHER) on doxorubicin (DOX)-induced cardiotoxicity in a phase II study in patients with metastatic cancer. Eight patients with metastatic cancer were treated with DOX preceded by a 10 min i.v. infusion of 1500 mg m(−2) monoHER. Five patients were examined by endomyocardial biopsy after reaching a cumulative dose of 300 mg m(−2). Histopathological changes in the cardiomyocytes (Billingham score) were compared with those described in literature for patients treated with DOX only. The mean biopsy score of the patients was higher (2.7) than the mean score (1.4) of historical data of patients who received similar cumulative doses of DOX. Although there is a considerable variability in few investigated patients, it was indicative that monoHER enhanced DOX-induced cardiotoxicity. However, the antitumour activity of DOX seemed better than expected: three of the four patients with metastatic soft-tissue sarcoma had a partial remission and the fourth patient stable disease. It is likely that the relatively high dose of monoHER is responsible for the lack of cardioprotection and for the high response rate in patients with soft-tissue sarcoma possibly by depleting the glutathione defense system in both heart and tumour. Nature Publishing Group 2007-10-22 2007-10-16 /pmc/articles/PMC2360436/ /pubmed/17940501 http://dx.doi.org/10.1038/sj.bjc.6603994 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Translational Therapeutics
Bruynzeel, A M E
Niessen, H W M
Bronzwaer, J G F
van der Hoeven, J J M
Berkhof, J
Bast, A
van der Vijgh, W J F
van Groeningen, C J
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
title The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
title_full The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
title_fullStr The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
title_full_unstemmed The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
title_short The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study
title_sort effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase ii study
topic Translational Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360436/
https://www.ncbi.nlm.nih.gov/pubmed/17940501
http://dx.doi.org/10.1038/sj.bjc.6603994
work_keys_str_mv AT bruynzeelame theeffectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT niessenhwm theeffectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT bronzwaerjgf theeffectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT vanderhoevenjjm theeffectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT berkhofj theeffectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT basta theeffectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT vandervijghwjf theeffectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT vangroeningencj theeffectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT bruynzeelame effectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT niessenhwm effectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT bronzwaerjgf effectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT vanderhoevenjjm effectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT berkhofj effectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT basta effectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT vandervijghwjf effectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy
AT vangroeningencj effectofmonohydroxyethylrutosideondoxorubicininducedcardiotoxicityinpatientstreatedformetastaticcancerinaphaseiistudy